fda compounding semaglutide news today says that the GLP-1 shortage is over New project announcement: HHS‑OIG is

The FDA followed with enforcement actions throughout late 2025 and into 2026

Digestive changes are common and often most pronounced during the initial weeks of therapy or after dose escalations

Physiol Behav 206:232242 Bruns VN, Tressler EH, Vendruscolo LF et al (2024) IUPHAR review-Glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target

Nat Reviews Disease Primers

Decreased and/or low muscle and bone mass negatively impact health, including physical impairment or disability, falls and fractures, surgical complications, reduced quality of life, and decreased survival

This prolonged retention of food increases fermentation in the gut, producing more hydrogen sulfide gas that causes sulfur burps